XTI Aerospace Shares Are On The Rise Today: What's Going On?

XTI Aerospace Inc. XTIA shares are trading higher Tuesday after the company announced its 2025 strategic initiatives aimed at strengthening its leadership in the VTOL (Vertical Take-Off and Landing) and powered-lift aircraft markets.

What To Know: XTI Aerospace revealed plans for a 1-for-250 reverse stock split, which is set to take effect on Jan. 10, 2025. The reverse split, approved by shareholders during XTI’s 2024 Annual Meeting on Dec. 27, 2024, will consolidate every 250 shares of common stock into a single share. The stock will trade under the adjusted CUSIP number 98423K405.

Fractional shares resulting from the split will be rounded up to the nearest whole share and authorized shares and par value per share will remain unchanged. This consolidation is intended to boost XTI’s stock price to meet Nasdaq’s minimum bid price requirement and position the company for long-term growth.

Chairman and CEO Scott Pomeroy described the share consolidation as a necessary step to support the company’s broader initiatives and capitalize on the FAA’s recognition of the powered-lift category. He emphasized that this development marks a transformative era for the aviation industry, with XTI aiming to solidify its role as a leader in VTOL and powered-lift innovation.

XTI also highlighted its progress in 2024, including improvements to its balance sheet and capital structure. The company stated these changes have created a more stable financial platform to pursue strategic acquisitions, raise additional capital and expand its technological and market footprint.

The company reiterated its focus on the TriFan 600, its flagship product and its plans to leverage growth opportunities within the powered-lift market. XTI stated that it is building a comprehensive foundation to accelerate its development efforts and establish itself as a global leader in aviation.

XTIA Price Action: XTI Aerospace shares closed Tuesday up 29.66% at 11 cents, according to Benzinga Pro.

Read Next:

Photo Credits: Courtesy of XTI Aerospace, Inc.

Market News and Data brought to you by Benzinga APIs

Peter Lynch's Timeless Investment Rules: 'You Can Always Lose What You Have Invested, Even if a Stock Is Cheap'

Peter Lynch, legendary investor and former manager of Fidelity’s Magellan Fund, continues to inspire investors with his timeless principles.

What Happened: Lynch, who achieved a remarkable 29% compound annual return during the 1980s, shared key investment lessons in a 1997 speech that remain relevant today. His insights are a roadmap for navigating market fluctuations and identifying opportunities.

Lynch has emphasized that stock prices can defy expectations. Stocks can always go higher, he explained, particularly if the fundamentals of the underlying business are solid.

He warned against selling a rising stock purely because it seems overvalued, though he acknowledged the risks of inflated valuations. Short-term market sentiment, not fundamentals, often drives price movements.

“If a stock goes higher, especially if it’s a high-flying stock without the earnings to back it up, investors may think it couldn’t possibly go higher. If the fundamentals of the business are great, with sales and profits expanding, then the stock could still continue to rise higher, as the market’s short-term movements are often driven by sentiment, not reality,” Lynch said.

“The fact that a stock has gone higher is not a reason to sell in and of itself, though don’t forget that overvalued stocks are risky,” he further added.

Also Read: Investment Guru Peter Lynch: ‘If You Can’t Explain To An 11-Year-Old In 2 Minutes Or Less Why You Own The Stock, You Shouldn’t Own It’

Another critical point Lynch made is that a stock price decline doesn’t necessarily mean the investor was wrong. Short-term volatility doesn’t dictate the validity of a well-researched investment decision.

Lynch noted, “The average movement of a stock on the New York Stock Exchange this century has been 50% between its high and low.” Even strong stocks can experience significant temporary declines.

“The short-term movements of a stock price don’t determine whether you are right or wrong. Investing success cannot be determined by the initial outcome alone,” he added.

Lynch also reminded investors of the inherent risk in stock investing. He dispelled the myth that cheap stocks are inherently safer, pointing out that the potential loss is the same regardless of the stock’s initial price if it collapses entirely.

“Many people often forget that when investing, you can always lose what you have invested, even if a stock is cheap,” he said.

Lynch highlighted the importance of thorough research. He said that the person who turns over the most rocks wins, encouraging investors to scrutinize a broad range of companies to uncover mispriced opportunities.

If you look at 10 companies you will find one which is mispriced. If you look at 20 you will find two. The person who turns over the most rocks wins,” Lynch added.

Why It Matters: These principles, rooted in decades of experience, provide valuable guidance for investors navigating today’s dynamic markets.

By focusing on fundamentals, avoiding emotional decisions, and committing to rigorous analysis, Lynch’s approach underscores the keys to long-term success.

Read Next

Investment Guru Peter Lynch: ‘Often Great Investments Are The Ones Where Everyone Else Will Think You Are Crazy’

This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Market News and Data brought to you by Benzinga APIs

Siyata Mobile Shares Are On The Rise Friday: What's Going On?

Siyata Mobile Inc. SYTA shares are trading higher on Friday, possibly following the company’s announcement of a 1-for-10 reverse stock split on Tuesday.

What To Know: The move is aimed at maintaining compliance with Nasdaq’s $1 minimum bid price requirement. The reverse stock split will be effective on Dec. 27, 2024, with trading on a post-split basis commencing the same day under the ticker symbol “SYTA.”

The reverse stock split consolidates every 10 existing shares into one new share. Outstanding stock options, warrants and other convertible securities will also be adjusted to reflect the new ratio. No fractional shares will be issued, with fractions rounded up to the nearest whole number.

Siyata, a global provider of Push-to-Talk over Cellular devices and cellular signal boosters, clarified that the split does not affect the par value or authorized number of shares. The transfer agent, Computershare, will handle the exchange process for registered shareholders. Those holding shares electronically or through brokers will have their positions adjusted automatically.

Despite the stock price jump, the company warned there is no guarantee it will maintain compliance with the minimum bid price requirement after the split.

SYTA Price Action: Siyata Mobile shares were up 23.62% at $6.43 at publication Friday, according to Benzinga Pro.

Read Next:

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

Coeptis Therapeutics Announces Reverse Stock Split

WEXFORD, Pa., Dec. 27, 2024 /PRNewswire/ — Coeptis Therapeutics Holdings, Inc. COEP (the “Company” or “Coeptis”), a biopharmaceutical company focused on pioneering cell therapy platforms for cancer, autoimmune, and infectious diseases, today announced it will proceed with a 1-for-20 reverse stock split (the “Reverse Split”) of its issued and outstanding shares of common stock, par value $0.0001, following authorization by its board of directors (the “Board”) and majority stockholders to effect a reverse stock split by a ratio of not less than 1-for-3 and not more than 1-for-40 (the “Reverse Split Range”), with the Board having the discretion as to whether or not the Reverse Split is to be effected, and the exact ratio to be set at a whole number within the Reverse Split Range.

The first day of trading on a post-split basis on the Nasdaq Capital Market, will be at market open on December 31, 2024.

Upon the effective date of the Reverse Split, every 20 shares of the Company’s outstanding and issued common stock will be converted into one share of outstanding and issued common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, any fractional shares for record holders that would have resulted from the split will be rounded up to the next whole number. The Reverse Split will not alter any stockholder’s percentage interest in the Company’s outstanding common stock, except for adjustments that may result from the treatment of fractional shares and will affect all stockholders uniformly.

The Reverse Split is intended to help the Company meet the minimum bid price requirement necessary to maintain its listing on the Nasdaq Capital Market. Under Nasdaq Capital Market rules, a listed company’s stock must maintain a minimum bid price of at least $1.00 per share.

The Reverse Split was approved by the Company’s stockholders at the Company’s Annual Stockholder’s Meeting on December 18, 2024, following which meeting the Board then established the reverse split ratio and authorized the reverse split to proceed.

Continental Stock Transfer is acting as the exchange agent and transfer agent for the reverse stock split and will send instructions to stockholders of record who hold stock certificates regarding the exchange of their old certificates for new certificates, should they wish to do so. Stockholders who hold their shares in brokerage accounts or “street name” are not required to take any action to affect the exchange of their shares.

About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc. (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis’ product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and leading medical researchers at the Karolinska Institute. The Company is headquartered in Wexford, PA. For more information on Coeptis visit https://coeptistx.com

Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain “forward-looking statements” (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company’s securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company’s products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (4) costs related to ongoing asset development including the Deverra licensed assets and pursuing the contemplated asset development paths; (5) changes in applicable laws or regulations; (6) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (7) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.

Contacts
IR@coeptistx.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-announces-reverse-stock-split-302339384.html

SOURCE Coeptis Therapeutics, Inc.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Investment Guru Peter Lynch: 'Often Great Investments Are The Ones Where Everyone Else Will Think You Are Crazy'

Peter Lynch, a renowned investor and former fund manager of the Magellan Fund at Fidelity Investments, achieved a legendary compound annual return of 29% during the 1980s.

What Happened: In a 1997 speech, Lynch shared key principles from his 25-year career that guided his success. He emphasized that these principles were timeless, applicable then, now, and for decades to come. Below are three of his essential investing lessons.

Lynch advises against bias towards specific stocks or industries. He emphasizes that great investment opportunities can be found in unexpected places, including companies facing bankruptcy or skepticism.

“There are great stocks everywhere, even those in bankruptcy or close to it. Often times great investments are the ones where everyone else will think you are crazy,” Lynch said during his speech.

Also Read: Investment Guru Peter Lynch: ‘If You Can’t Explain To An 11-Year-Old In 2 Minutes Or Less Why You Own The Stock, You Shouldn’t Own It’

Lynch recommends documenting the reasons for purchasing a stock. If those reasons no longer apply due to changes in the company’s story, it may be time to sell. “When the story changes, the investment thesis changes,” he asserts.

A critical point Lynch underscores is that a stock dropping significantly doesn’t mean it won’t fall further. “Stocks can always go lower,” he warns, citing the example of Polaroid, which plummeted from $140 to $18 over nine months. He also cautions against assuming stocks will rebound solely because they’ve declined.

“Stocks also don’t have to bounce back just because they went down,” he added.

Why It Matters: These principles highlight Lynch’s disciplined and thoughtful approach to investing, which continues to inspire investors today.

Lynch’s principles offer timeless guidance for investors at all levels, from beginners to seasoned professionals. His focus on deeply understanding the business, prioritizing individual stock analysis, and exercising patience mirrors the strategies of legendary investors like Warren Buffett.

These insights serve as a powerful reminder that true success in investing comes not from chasing short-term gains but from making well-informed decisions and committing to a long-term

Read Next

Stock Market Predictions for 2025: A Mixed Bag Of Expectations

Market News and Data brought to you by Benzinga APIs

Netflix Surges Past $900. Is Stock Split On The Cards? Analyst Says Such Move 'Wouldn't Surprise Us'

Netflix Inc. NFLX has witnessed its stock price soar beyond $900, sparking speculation about a potential stock split. This surge aligns with a broader market rally, particularly in Big Tech, driven by advancements in AI software and chips.

What Happened: Netflix’s shares have increased more than fivefold since hitting a low in 2022. The S&P 500 has risen 70% since the bear market bottomed in October 2022. Companies like Nvidia Corp. NVDA and Deckers Outdoor Corp. DECK have already executed stock splits this year, Barron’s reported on Friday.

Ken Mahoney of Mahoney Asset Management commented, “Once stocks are worth way into the high hundreds of dollars per share range, a lot of people get in their mind that a stock split could be coming.”

“It wouldn’t surprise us if Netflix followed suit within the next few announcing earnings.”

A stock split can attract more investors by making shares more affordable, potentially boosting market value.

Netflix has yet to respond to Benzinga’s queries.

See Also: Cathie Wood’s Ark Invest Trims Tesla Exposure Amid Searing Rally, Sells $21.8M Worth Of Stock — Bets On This AI Medical Company

Netflix’s growth, particularly outside the U.S., and increased profit margins have contributed to its rising stock price. Analysts anticipate further revenue growth through higher international subscription prices and advertising. However, Netflix’s high valuation could deter some investors if earnings expectations are not met.

Why It Matters: The recent surge in Netflix’s stock price is not an isolated event. Jim Cramer recently expressed strong buying conviction for Netflix as its shares traded near $934. This comes amid broader tech market strength and a recommendation from JPMorgan analyst Doug Anmuth, who raised his price target on Netflix to $1,010 from $850. Anmuth cited robust subscriber growth and expanding ad revenue as key factors.

Netflix’s recent milestone, the Jake Paul vs. Mike Tyson boxing match, became the most-streamed sporting event ever, with 60 million households watching live. This achievement underscores the platform’s growing influence in the streaming industry and its ability to attract a massive audience.

Price Action: According to Benzinga Pro, Netflix was trading slightly higher at $204.60 on Friday during pre-market hours after previously closing at $203.68.

Meanwhile, as per the three most-recent analyst ratings, released by JP Morgan, Citigroup, and Canaccord Genuity the average price target of Netflix is $956.67, with an implied 3.48% upside for the company.

Read Next: 

Disclaimer: This content was partially produced with the help of Benzinga Neuro and was reviewed and published by Benzinga editors.

Image via Pixabay

Market News and Data brought to you by Benzinga APIs

MMTEC, Inc. Announces 1-for-8 Reverse Stock Split

HONG KONG, Dec. 12, 2024 /PRNewswire/ — MMTEC, Inc. (“MMTEC” or the “Company”) MTC reported that it expects to implement a 1-for-8 reverse stock split on its common stock. The effective date is scheduled to be December 18, 2024, subject to the Company’s satisfaction of Nasdaq Operations notice requirements, with trading to begin on a split-adjusted basis at the market open on that day. Trading in the common stock will continue on the Nasdaq Stock Market under the symbol “MTC”. The new CUSIP number for the common stock following the reverse stock split will be G6181K122. In the event that the effective date is delayed, the Company will update the effective date via a subsequent press release.

The reverse stock split at a ratio of 1-for-8 shares was approved by the Company’s Board of Directors.

Upon the effectiveness of the reverse stock split, every 8 shares of the Company’s issued and outstanding common stock will automatically be converted into one share of issued and outstanding common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split will be rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s outstanding common stock, except for adjustments that may result from the treatment of fractional shares.

In connection with the reverse stock split, the Company filed a Second Amended and Restated Memorandum of Association with the Registry of Corporate Affairs of the British Virgin Islands to reduce the authorized number of shares of the Company’s common stock from 5,000,000,000 shares to 625,000,000 shares, the reduction at the same ratio as its reduction in the issued and outstanding shares of common stock, and to increase the par value per share from $0.01 to $0.08. The Board of Directors of the Company approved the reverse stock split on November 21, 2024. No stockholders’ approval of the reverse stock split is required pursuant to BVI law.

About MMTEC, Inc.

Headquartered in Hong Kong Special Administrative Region, our Company mainly focuses on investment banking and asset management business, providing customers with one-stop and all-round financial services.

More information about the Company can be found at: www.haisc.com

Forward-Looking Statements

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may”, “will”, “intend”, “should”, “believe”, “expect”, “anticipate”, “project”, “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Specifically, the Company’s statements regarding its ability to regain compliance with the Bid Price Rule, its continued growth, its business outlook, and other similar statements are forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission, including the Company’s most recently filed Annual Report on Form 20-F and its subsequent filings. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the U.S. Securities and Exchange Commission, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Cision View original content:https://www.prnewswire.com/news-releases/mmtec-inc-announces-1-for-8-reverse-stock-split-302330177.html

SOURCE MMTEC, Inc.

Market News and Data brought to you by Benzinga APIs

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

Mainz Biomed N.V. MYNZ announced a 1-for-40 reverse stock split, effective Dec. 3. The company specializes in the early detection of cancer.

Last month, Mainz Biomed reported a collaborative agreement with Thermo Fisher Scientific Inc. TMO through its subsidiary Life Technologies Corporation.

The collaboration agreement will enable Mainz Biomed and Thermo Fisher to jointly develop and potentially commercialize Mainz Biomed’s Next Generation colorectal cancer screening product.

The collaboration will harness Thermo Fisher’s technologies, instrumentation and information translation systems to enable Mainz Biomed to develop proprietary assays for its mRNA-based next-generation colorectal cancer screening tests.

Mainz Biomed’s flagship non-invasive test targets the early detection of colorectal cancer and focuses on precancerous lesions, particularly advanced adenomas.

The collaboration will leverage combined capabilities to deliver testing solutions being developed at Mainz Biomed’s laboratories in Mainz, Germany.

Guido Baechler, CEO of Mainz Biomed, said: “This collaboration with Thermo Fisher will be instrumental to our goal to bring to market a home collection colorectal screening tool with highly effective detection of adenomas.”

In October, Mainz Biomed reported a 4% increase in revenue and a 32% decrease in operational losses for the first half of 2024. These decreases result from the company’s efforts to reduce costs during the first half of the year.

The company announced significant improvements to its ColoAlert product, which is available across Europe and in select international markets.

The company says that the new proprietary buffer used in ColoAlert significantly reduces the necessity for additional sample submissions, thereby decreasing how long it takes patients to obtain their results.

This enhancement enabled ColoAlert to achieve the industry’s lowest retesting rates, ensuring that screening outcomes are delivered within two to three days of arrival at the laboratory.

Price Action: MYNZ stock is down 13.09% at $6.93 at publication Tuesday.

Read Next:

Photo: Shutterstock

Market News and Data brought to you by Benzinga APIs

Citius Pharmaceuticals, Inc. Announces 1-for-25 Reverse Stock Split

CRANFORD, N.J., Nov. 22, 2024 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius Pharma” or the “Company”) CTXR announced today that it will be executing a reverse stock split of its common stock, par value $0.001 per share, at a ratio of 1-for-25 (“Reverse Stock Split”). Pursuant to the laws of the State of Nevada and subject to prior approval by the Company’s Board of Directors, Citius Pharma was not required to obtain shareholder approval to effectuate the Reverse Stock Split. The Reverse Stock Split will become effective at 5:00 pm Eastern Time on November 25, 2024. The Company’s common stock will begin trading on the Nasdaq Capital Market on a split-adjusted basis beginning upon market open on November 26, 2024, under the Company’s existing trading symbol “CTXR” with the new CUSIP number 17322U306.

The Reverse Stock Split is intended to increase the per share trading price of Citius Pharma’s common stock to regain compliance with the minimum bid price requirement of $1.00 per share of common stock for continued listing on the Nasdaq Capital Market. Under Section 78.207 of the Nevada Revised Statutes, the Company may decrease its authorized shares of Common Stock and correspondingly decrease the number of issued and outstanding shares of Common Stock by resolution adopted by the Board of Directors, without obtaining the approval of the stockholders. The Reverse Stock Split was approved by the Company’s Board of Directors pursuant to the Nevada Revised Statutes and was effectuated by the filing of a Certificate of Change with office of the Nevada Secretary of State.

At the effective time of the Reverse Stock Split, every twenty-five (25) issued and outstanding shares of the Company’s common stock will be combined automatically into one (1) share of the Company’s common stock without any change in the par value per share. No fractional shares will be issued in connection with the reverse stock split, and any fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole share at the participant level.

The reverse stock split will reduce the number of authorized shares of the Company’s common stock from 400 million shares to 16 million shares and the ownership percentage of each stockholder will remain unchanged other than as a result of the rounding of fractional shares. The Reverse Stock Split will reduce the number of issued and outstanding shares of the Company’s common stock from approximately 193 million to approximately 7.7 million.

In addition, the Reverse Stock Split will apply to the Company’s common stock issuable upon the exercise of the Company’s outstanding warrants and stock options, with proportionate adjustments to be made to the exercise prices thereof and under the Company’s equity incentive plans, as applicable.

The Company’s transfer agent, VStock Transfer LLC, will act as the exchange agent for the reverse stock split. Stockholders holding their shares in book-entry form or in “street name” through a bank, broker, or other nominee will not need to take any action in connection with the reverse stock split.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR™, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma’s late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit www.citiuspharma.com.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as “will,” “anticipate,” “estimate,” “expect,” “plan,” “should,” and “may” and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price.  Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Pharma and Citius Oncology, are: the potential impact of the reverse split on the bid price of the Company’s common stock; Citius Pharma’s ability to regain compliance with and continue to meet Nasdaq’s continued listing standards; our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; risks relating to the results of research and development activities, including those from our existing and any new pipeline assets; risks related to research using our assets but conducted by third parties; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; the early stage of products under development; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our SEC filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings which are available on the SEC’s website at www.sec.gov, including in Citius Pharma’s Annual Report on Form 10-K for the year ended September 30, 2023, filed with the SEC on December 29, 2023, as updated by our subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Investor Relations for Citius Pharmaceuticals:

Investor Contact:
Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

Media Contact:
STiR-communications
Greg Salsburg
Greg@STiR-communications.com 

Citius Pharmaceuticals, a late-stage biopharmaceutical company (PRNewsfoto/Citius Pharmaceuticals, Inc.)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-announces-1-for-25-reverse-stock-split-302313772.html

SOURCE Citius Pharmaceuticals, Inc.

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

SKRR Exploration Inc. Announces TSXV Approval of Consolidation

VANCOUVER, BC, Nov. 25, 2024 /CNW/ – SKRR Exploration Inc. SKRR (FSE: B04Q) (“SKRR” or the “Company“) announces that, further to its news release dated November 19, 2024, the TSX Venture Exchange (the “Exchange“) has approved the consolidation of the Company’s common shares (the “Consolidation“) on the basis of one (1) post-Consolidation common share for every four (4) pre-Consolidation common shares. The Consolidation will be effective at the opening of the market on November 27, 2024 (the “Effective Date“). Pursuant to the provisions of the Business Corporations Act (British Columbia) and the Articles of the Company, the Consolidation was approved by way of resolution passed by the board of directors of the Company.

The Company’s name and trading symbol will remain unchanged following the Consolidation. The new CUSIP number will be 78446Q308 and the new ISIN number will be CA78446Q3089 for the post-Consolidation common shares. The Company currently has 19,375,371 common shares issued and outstanding, and after the Consolidation is effective there will be approximately 4,843,842 common shares issued and outstanding.

Any fractional post-Consolidation share that is less than one-half (1/2) of a share will be cancelled and any fractional post-Consolidation share that is at least or greater than one-half (1/2) of a share will be rounded up to one whole share. Registered shareholders of record as of the Effective Date who hold physical share certificates will receive a letter of transmittal from the Company’s transfer agent, Computershare Investor Services Inc., with instructions on how to exchange for new share certificates representing post-Consolidation shares. Beneficial shareholders who hold their shares through a broker or other intermediary and do not have shares registered in their own names will not be required to complete a letter of transmittal.

About SKRR Exploration Inc.

SKRR is a Canadian-based precious and base metal explorer with properties in Saskatchewan – some of the world’s highest ranked mining jurisdictions. The primary exploration focus is on the Trans-Hudson Corridor in Saskatchewan in search of world class uranium, precious, and base metal deposits. The Trans-Hudson Orogen – although extremely well known in geological terms has been significantly under-explored in Saskatchewan. SKRR is committed to all stakeholders including shareholders, all its partners and the environment in which it operates.

ON BEHALF OF THE BOARD

Sherman Dahl
President & CEO
Tel: 250-558-8340

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This news release contains “forward–looking information or statements” within the meaning of applicable securities laws, which may include, without limitation, statements relating to the Consolidation being effected on the stated date, statements relating to the technical, financial and business prospects of the Company, its projects, its goals and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of metals, the ability to achieve its goals, the ability to secure equipment and personnel to carry out work programs, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms. Such forward-looking information reflects the Company’s views with respect to future events and is subject to risks, uncertainties and assumptions, including the risks and uncertainties relating to the interpretation of exploration results, risks related to the inherent uncertainty of exploration and cost estimates and the potential for unexpected costs and expenses and those other risks filed under the Company’s profile on SEDAR+ at www.sedarplus.ca. There is a possibility that future exploration, development or mining results will not be consistent with the Company’s expectations. Factors that could cause actual results to differ materially from those in forward looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, failure to secure personnel and equipment for work programs, adverse weather and climate conditions, failure to obtain or maintain all necessary government permits, approvals and authorizations, decrease in the price of gold, copper, uranium and other metals, failure to obtain or maintain community acceptance (including First Nations), increase in costs, litigation, and failure of counterparties to perform their contractual obligations. The Company does not undertake to update forward–looking statements or forward–looking information, except as required by law.

 

SOURCE SKRR Exploration Inc.

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/November2024/25/c9341.html

Market News and Data brought to you by Benzinga APIs

background

Stay Ahead with StockBurger!

Real-time meme stock trends powered by social media insights. Be the first to know about new market waves.

hand